Alzheimer’s Disease Therapeutics and Diagnostics Market Outlook 2022-2028

 

Triton Market Research presents the Global Alzheimer’s Disease Therapeutics and Diagnostics Market report segmented by Therapeutics (Disease Stage [Prodromal Stage, Early/Middle Stage: Mild To Moderate AD, Late Stage: Severe AD], Drug Type [Marketed Drugs, Pipeline Drugs], Generic & Branded [Branded, Generic]), by Diagnostics (Magnetic Resonance Imaging, Positron Emission Tomography, Blood Test, Computed Tomography, Electroencephalography, Lumbar Puncture Test, Other Diagnostics), by Geographical Region (North America, Europe, Asia-Pacific, Latin America, Middle East and Africa), discussing Market Summary, Industry Outlook, Market Drivers, Market Challenges, Market Opportunities, Competitive Landscape, Research Methodology & Scope, and Global Market Size, Forecasts, & Analysis (2022-2028).

Triton Market Research’s report has put forth that the Global Alzheimer’s Disease Therapeutics and Diagnostics Market is likely to evolve at a CAGR of 6.98% over the estimated duration 2022-2028.

 


Request Free sample:

https://www.tritonmarketresearch.com/reports/alzheimers-disease-therapeutics-and-diagnostic-market#request-free-sample

 

According to United Nations’ World Population Prospects 2019, 1 in every 6 people in the world will be above the age of 65 years by 2050. Due to aging, people in this age group are more prone to developing neurological conditions. The year-over-year expanding aging populace is expected to increase the prevalence of Alzheimer’s disease, and, consequently, boost the demand for therapeutics and diagnostics.

Regulations set by the US Food and Drug Administration require any company intending to manufacture a new drug to seek approval from the regulatory body prior to conducting clinical trials in the country. Regulations pertaining to drug development and commercialization negatively affect the market growth.

North America dominated the global market in 2021 with the highest share, and is anticipated to continue this dominance until the end of the forecasted period. An increasing aging populace, the presence of leading market players, and increased investments in research & development have substantially enhanced the demand for therapeutics and diagnostics in the region. This, in turn, is driving the market growth in North America.

Merck and Co, Johnson and Johnson, Eli Lilly & Company, Allergan Plc (acquired by Abbvie), Zydus Cadila, GE Healthcare, Eisai Co Ltd, Baxter International Inc, Siemens Healthineers AG, Novartis AG, Pfizer Inc, F. Hoffmann-La Roche AG, Teva Pharmaceutical Industries Ltd, Amarantus Bioscience Holdings Inc, Lupin Limited, Cognoptix Inc, Sun Pharmaceuticals Industries Ltd, and Biogen Inc are some of the eminent players in the market.

Although many alternative therapies for AD diagnosis and treatment are not available, the introduction of generic drugs and novel diagnostic methodologies has led to increased internal substitution. And with the introduction of these drugs, the competition among market players for developing new treatment and diagnostics methodologies has increased significantly. Besides, the industry is also witnessing meaningful strategic partnerships. A high disease burden and the lack of disease-modifying therapies also present opportunities for novel products.

 

Contact Us:

sales@tritonmarketresearch.com

Phone: +44 7441 911839

Comments

Post a Comment

Popular posts from this blog

NORTH AMERICA BIOCHAR MARKET 2022-2028

    TABLE OF CONTENTS 1. NORTH AMERICA BIOCHAR MARKET - SUMMARY 2. INDUSTRY OUTLOOK 2.1. IMPACT OF COVID-19 ON BIOCHAR MARKET 2.2. KEY INSIGHTS 2.2.1. PYROLYSIS IS THE MOST COMMON TECHNIQUE FOR BIOCHAR PRODUCTION 2.2.2. AGRICULTURE DOMINATES THE APPLICATION SEGMENT 2.2.3. GROWING NEED TO AVOID BIOCHAR LOSS DURING APPLICATION AND TRANSPORTATION 2.3. PORTER’S FIVE FORCES ANALYSIS 2.3.1. THREAT OF NEW ENTRANTS 2.3.2. THREAT OF SUBSTITUTES 2.3.3. BARGAINING POWER OF BUYERS 2.3.4. BARGAINING POWER OF SUPPLIERS 2.3.5. THREAT OF COMPETITIVE RIVALRY 2.4. KEY IMPACT ANALYSIS 2.5. MARKET ATTRACTIVENESS INDEX 2.6. VENDOR SCORECARD 2.7. INDUSTRY COMPONENTS 2.8. REGULATORY FRAMEWORK 2.9. KEY MARKET STRATEGIES 2.9.1. PRODUCT LAUNCHES & DEVELOPMENTS 2.9.2. PARTNERSHIPS & AGREEMENTS 2.10. MARKET DRIVERS 2.10.1. FAVORABLE INITIATIVES 2.10.2. AVAILABILITY OF CHEAP FEEDSTOCK 2.10.3. ABILITY OF BIOCHAR TO SEQUESTER CARBON 2.10.4. RELIA...
Read more

ITALY ALCOHOLIC READY-TO-DRINKS (RTDS) MARKET 2021-2026

    TABLE OF CONTENT 1.      ITALY ALCOHOLIC READY-TO-DRINKS (RTDS) MARKET –SUMMARY 1.1. COUNTRY SNAPSHOT 1.2. MARKET SIZE & FORECAST 1.3. MARKET DRIVING ASPECTS 1.4. MARKET RESTRAINING ASPECTS 1.5. KEY PLAYERS 2.      ITALY ALCOHOLIC READY-TO-DRINKS (RTDS) MARKET OUTLOOK 2.1. IMPACT OF COVID-19 ON ITALY ALCOHOLIC RTDS MARKET 2.2. PESTLE ANALYSIS 2.2.1.     POLITICAL 2.2.2.     ECONOMICAL 2.2.3.     SOCIAL 2.2.4.     TECHNOLOGICAL 2.2.5.     LEGAL 2.2.6.     ENVIRONMENTAL 2.3. MARKET ATTRACTIVENESS INDEX 2.4. MARKET SHARE ANALYSIS OF KEY PLAYERS 2.5. BRAND SHARE ANALYSIS 3.      ITALY ALCOHOLIC RTD MARKET SEGMENTATION - BY RTD TYPE (IN TERMS OF VALUE: $ MILLION & IN TERMS OF VOLUME: MILLION LITRES) 3.1. SPIRIT-BASED RTDS 3.2. WINE-BASED RTDS 4.    ...
Read more

GLOBAL ENTERPRISE RESOURCE PLANNING MARKET 2022-2028

    TABLE OF CONTENTS   1.      GLOBAL ENTERPRISE RESOURCE PLANNING MARKET - SUMMARY 2.      INDUSTRY OUTLOOK 2.1. IMPACT OF COVID-19 ON ENTERPRISE RESOURCE PLANNING MARKET 2.2. PARENT MARKET ANALYSIS: ENTERPRISE APPLICATION MARKET 2.3. TIMELINE OF ENTERPRISE RESOURCE PLANNING (ERP) 2.4. KEY INSIGHTS 2.4.1.     EMERGENCE OF CLOUD ERP 2.4.2.     SOCIAL NETWORKING IS GAINING IMPORTANCE AMONG ERP MERCHANTS 2.4.3.     INTEGRATED ERP IS ONE OF THE PROMINENT EMERGING TRENDS 2.4.4.     ACQUISITION HAS EMERGED AS A PRIMARY GROWTH STRATEGY 2.5. PORTER’S FIVE FORCES ANALYSIS 2.5.1.     THREAT OF NEW ENTRANTS 2.5.2.     THREAT OF SUBSTITUTES 2.5.3.     BARGAINING POWER OF BUYERS 2.5.4.     BARGAINING POWER OF SUPPLIERS 2.5.5.     THREAT OF COMPETITIVE RIVALRY 2.6. KEY...
Read more